222 West Las Colinas Boulevard
Suite 900N
Irving, TX 75039
E: healthcare@celanese.com
W: www.celanese.com  


REGISTER NOW! Celanese Live Webinar: Engineering Drug Delivery to Improve Therapeutic Outcomes – September 9, 2021




Laura Brand, VP, on Celanese Solutions for Long-Acting Dosage Forms
Read the DD&D Executive Interview with Laura Brand, Vice President of Celanese’s Medical & Pharmaceutical Business, to learn how a strong understanding of customer challenges enables Celanese to be a true partner in drug pipeline development, allowing pharmaceutical companies and channel partners to rethink how medications are delivered and open the door to opportunities to enhance a drug’s impact on patient outcomes.





Celanese works closely with you as a strategic partner to create innovative controlled-release dosage forms for biologics and small molecules to meet the goals of patient-centric therapies, improved medicine and better healthcare economics.


Our scientists and engineers are there from concept to commercialization, providing development services, material supply aligned with GMP principles and regulatory support. Our objective is to help our customers reduce time and risk in research and development, so their drug achieves a higher chance of success.

Our VitalDose® Ethylene-Vinyl Acetate (EVA) copolymer drug-delivery platform is an enabling technology for drug-eluting implants, inserts and transdermal films. The platform is flexible and customizable to address a variety of formulation challenges when it comes to tailoring the release rate of your drug.

  • Compatible with biologics and small molecules
  • Provides reliable local or systemic drug administration
  • High drug loading capacity (≤ 75%)
  • Engineered long-acting dosage profiles (zero-order or nonlinear profiles)
  • Ease of formulation and configurable into a variety of geometries
  • An established regulatory path with long clinical use history

VitalDose® EVA has been approved for use in numerous pharmaceutical and medical device applications. We are actively supporting marketed products and development programs in:

  • Oncology
  • Infectious diseases
  • Central nervous system disorders
  • Ophthalmic inserts & intraocular implants
  • Women’s health
  • Cardiovascular devices


Celanese Corporation is a global technology leader in the production of differentiated chemistry solutions and specialty materials used in most major industries and consumer applications. Our businesses use the full breadth of Celanese’s global chemistry, technology and commercial expertise to create value for our customers, employees, shareholders and the corporation. As we partner with our customers to solve their most critical business needs, we strive to make a positive impact on our communities and the world through The Celanese Foundation. Based in Dallas, Celanese employs approximately 7,700 employees worldwide and had 2019 net sales of $6.3 billion.

Celanese has supported key applications and the demanding requirements of the medical market for over 40 years and has developed one of the broadest ranges of special thermoplastics in the world. We are expanding design possibilities as our customers find new ways to improve patient care with cutting-edge medical and pharmaceutical material solutions. Our continuously expanding Medical Technology portfolio includes solutions and technologies for multiple applications in the space of drug delivery, medical devices, orthopedics, advanced surgical instruments and connected devices.